(1) A drug prior approval program approved or implemented by the board shall meet the following conditions: (a) except as provided in Subsection (2), a drug may not be placed on prior approval for other than medical reasons; (b) the board shall hold a public hearing at least 30 days prior to placing a drug on prior approval; (c) notwithstanding the provisions of Section 52-4-202, the board shall provide not less than 14 days' notice to the public before holding a public hearing under Subsection (1)(b); (d) the board shall consider written and oral comments submitted by interested parties prior to or during the hearing held in accordance with Subsection (1)(b); (e) the board shall provide evidence that placing a drug class on prior approval: (i) will not impede quality of recipient care; and (ii) that the drug class is subject to clinical abuse or misuse; (f) the board shall reconsider its decision to place a drug on prior approval: (i) no later than nine months after any drug class is placed on prior approval; and (ii) at a public hearing with notice as provided in Subsection (1)(b); (g) the program shall provide an approval or denial of a request for prior approval: (i) by either: (A) fax; (B) telephone; or (C) electronic transmission; (ii) at least Monday through Friday, except for state holidays; and (iii) within 24 hours after receipt of the prior approval request; (h) the program shall provide for the dispensing of at least a 72-hour supply of the drug on the prior approval program: (i) in an emergency situation; or (ii) on weekends or state holidays; (i) the program may be applied to allow acceptable medical use of a drug on prior approval for appropriate off-label indications; and (j) before placing a drug class on the prior approval program, the board shall: (i) determine that the requirements of Subsections (1)(a) through (i) have been met; and (ii) by majority vote, place the drug class on prior approval.

(a) except as provided in Subsection (2), a drug may not be placed on prior approval for other than medical reasons;

(b) the board shall hold a public hearing at least 30 days prior to placing a drug on prior approval;

(c) notwithstanding the provisions of Section 52-4-202, the board shall provide not less than 14 days' notice to the public before holding a public hearing under Subsection (1)(b);

(d) the board shall consider written and oral comments submitted by interested parties prior to or during the hearing held in accordance with Subsection (1)(b);

(e) the board shall provide evidence that placing a drug class on prior approval: (i) will not impede quality of recipient care; and (ii) that the drug class is subject to clinical abuse or misuse;

(i) will not impede quality of recipient care; and

(ii) that the drug class is subject to clinical abuse or misuse;

(f) the board shall reconsider its decision to place a drug on prior approval: (i) no later than nine months after any drug class is placed on prior approval; and (ii) at a public hearing with notice as provided in Subsection (1)(b);

(i) no later than nine months after any drug class is placed on prior approval; and

(ii) at a public hearing with notice as provided in Subsection (1)(b);

(g) the program shall provide an approval or denial of a request for prior approval: (i) by either: (A) fax; (B) telephone; or (C) electronic transmission; (ii) at least Monday through Friday, except for state holidays; and (iii) within 24 hours after receipt of the prior approval request;

(i) by either: (A) fax; (B) telephone; or (C) electronic transmission;

(A) fax;

(B) telephone; or

(C) electronic transmission;

(ii) at least Monday through Friday, except for state holidays; and

(iii) within 24 hours after receipt of the prior approval request;

(h) the program shall provide for the dispensing of at least a 72-hour supply of the drug on the prior approval program: (i) in an emergency situation; or (ii) on weekends or state holidays;

(i) in an emergency situation; or

(ii) on weekends or state holidays;

(i) the program may be applied to allow acceptable medical use of a drug on prior approval for appropriate off-label indications; and

(j) before placing a drug class on the prior approval program, the board shall: (i) determine that the requirements of Subsections (1)(a) through (i) have been met; and (ii) by majority vote, place the drug class on prior approval.

(i) determine that the requirements of Subsections (1)(a) through (i) have been met; and

(ii) by majority vote, place the drug class on prior approval.

(2) The board may, only after complying with Subsections (1)(b) through (j), consider the cost: (a) of a drug when placing a drug on the prior approval program; and (b) associated with including, or excluding a drug from the prior approval process, including: (i) potential side effects associated with a drug; or (ii) potential hospitalizations or other complications that may occur as a result of a drug's inclusion on the prior approval process.

(a) of a drug when placing a drug on the prior approval program; and

(b) associated with including, or excluding a drug from the prior approval process, including: (i) potential side effects associated with a drug; or (ii) potential hospitalizations or other complications that may occur as a result of a drug's inclusion on the prior approval process.

(i) potential side effects associated with a drug; or

(ii) potential hospitalizations or other complications that may occur as a result of a drug's inclusion on the prior approval process.